Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLIVY vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
In combination with bendamustine and rituximab for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies.,In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
The terminal elimination half-life of polatuzumab vedotin is approximately 12 days (range 8–20 days) for the antibody-drug conjugate. This supports a dosing interval of every 3 weeks. The half-life may be prolonged in patients with severe hepatic impairment.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
MMAE is primarily metabolized via CYP3A4/5. Less than 10% is metabolized by other CYP isoforms (1A2, 2C9, 2D6, 2E1, 3A4).
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Polivy (polatuzumab vedotin) is eliminated primarily through catabolism into small peptides and amino acids. The antibody-drug conjugate is not significantly excreted renally as intact compound; approximately <1% of the dose is excreted unchanged in urine. The majority of the drug is metabolized and eliminated via biliary/fecal routes, with approximately 80% of the total dose recovered in feces over 3 weeks, primarily as metabolites.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
The conjugate is highly protein-bound (>97%), primarily to plasma proteins such as albumin. The free drug (unconjugated MMAE) is approximately 70–80% bound to albumin.
47% bound to human plasma proteins, primarily albumin.
The volume of distribution at steady state is approximately 3.4 L (range 2.8–5.6 L), which corresponds to about 0.049 L/kg (assuming 70 kg). This small Vd indicates limited extravascular distribution, consistent with a large antibody-drug conjugate that remains primarily in the vascular space.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Bioavailability is 100% for the intravenous route. No oral formulation exists; the drug is administered only as an intravenous infusion.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Safety and efficacy not established in pediatric patients.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment recommended for elderly patients; monitor for increased toxicity, particularly infections and myelosuppression.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
No FDA black box warning.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Peripheral neuropathy: Monitor for new or worsening neuropathy; may require dose modification or discontinuation.,Infusion-related reactions: Premedicate with antihistamines and antipyretics; monitor during infusion.,Myelosuppression: Neutropenia, thrombocytopenia, and anemia; monitor blood counts regularly.,Infections: Increased risk of serious infections, including opportunistic infections.,Hepatotoxicity: Elevations of liver enzymes; monitor liver function.,Pneumonitis: Interstitial lung disease; monitor for pulmonary symptoms.,Tumor lysis syndrome: Monitor patients at risk and manage accordingly.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
Concomitant use with strong CYP3A4 inhibitors or inducers (avoid due to potential alteration of MMAE exposure).,Hypersensitivity to polatuzumab vedotin or any component of the formulation.
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions have been reported. Maintain adequate hydration. Avoid grapefruit or grapefruit juice if also taking certain CYP3A4 substrates, but no direct interaction with POLIVY.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Based on its mechanism of action as an antibody-drug conjugate targeting CD79b, POLIVY (polatuzumab vedotin-piiq) is expected to cause fetal harm when administered to pregnant women. There are no adequate and well-controlled studies in pregnant women. Verifies embryolethal and teratogenic effects in animal studies. The drug should be avoided during pregnancy, and women of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
There is no information regarding the presence of polatuzumab vedotin in human milk, its effects on the breastfed infant, or its effects on milk production. Due to the potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment with POLIVY and for at least 3 months after the final dose. M/P ratio is not known.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No specific dose adjustment recommendations are available for pregnancy due to lack of pharmacokinetic data in pregnant women. The drug is not recommended for use during pregnancy. If treatment must be administered during pregnancy, use the standard adult dose based on body weight (1.8 mg/kg actual body weight) as a 90-minute IV infusion every 21 days in combination with other agents. Monitor for toxicity and consider dose modifications for adverse events per standard guidelines.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
POLIVY (polatuzumab vedotin-piiq) is an antibody-drug conjugate targeting CD79b, used in combination with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Monitor for infusion-related reactions, peripheral neuropathy, and myelosuppression. Pre-medicate with antihistamines and antipyretics. Avoid in patients with moderate to severe hepatic impairment.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
This drug is given as an intravenous infusion; you may experience allergic reactions during or after infusion.,Report any numbness, tingling, or weakness in your hands or feet immediately.,You will have regular blood tests to monitor your blood cell counts and liver function.,Use effective contraception during treatment and for at least 3 months after the last dose.,Do not receive live vaccines while on this medication.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLIVY vs CLOLAR, answered by our medical review team.
POLIVY is a Antineoplastic Agent that works by Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLIVY and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLIVY is: 1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLIVY and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLIVY is classified as Category C. Based on its mechanism of action as an antibody-drug conjugate targeting CD79b, POLIVY (polatuzumab vedotin-piiq) is expected to cause fetal harm when administered to pregnant wome. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.